2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.
John O. Mascarenhas, MD, professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, the Center of Excellence for Blood Cancers and Myeloid Disorders, member, the Tisch Cancer Institute, discusses the investigation of pelabresib (CPI-0610) in myelofibrosis.
The phase 2 MANIFEST trial (NCT02158858) is investigating pelabresib, an oral BET inhibitor, alone and in combination with ruxolitinib (Jakafi) in patients who have failed ruxolitinib or another JAK inhibitor. Additionally, the combination is being explored in patients who have not received prior treatment with a JAK inhibitor, Mascarenhas explains.
Preclinical data showed that the combination of ruxolitinib and pelabresib was synergistic in improving aspects of myelofibrosis in mice, leading to the MANIFEST trial, Mascarenhas continues. The trial aims to evaluate the use of single-agent and combination pelabresib, both in later-line and up-front settings, Mascarenhas concludes.